Journal profile · Medicine-General Medicine
Biopreparaty Profilaktika diagnostika lechenie
ISSN 2221-996X · eISSN 2619-1156 · Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» · Russian Federation
Biopreparaty Profilaktika diagnostika lechenie: diamond open access (no APC); no APC; review about 8 weeks (community reports); acceptance rate 74% (journal website); 41 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Biopreparaty Profilaktika diagnostika lechenie is published by Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products». By OpenAlex counts of its recent articles, its largest topics are Biosimilars and Bioanalytical Methods, Analytical Methods in Pharmaceuticals and Bacterial Infections and Vaccines, together about 27.4% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
«БИОпрепараты. Профилактика, диагностика, лечение» – научно-практический рецензируемый журнал открытого доступа, учредителем которого выступает федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации (ФГБУ «НЦЭСМП» Минздрава России). Журнал является единственным изданием в России, посвященным полному циклу разработки биологических лекарственных препаратов и их медицинскому применению. Цель журнала – освещение актуальных вопросов разработки регуляторных процедур, стандартизации, контроля качества, производства терапевтических, профилактических и диагностических биологических лекарственных препаратов, биомедицинских клеточных продуктов и их применения, включая клинические аспекты, для профилактики, диагностики и лечения инфекционных заболеваний, изучения аллергических и иммунопатологических процессов. Целевая аудитория. Биотехнологи, иммунологи, вирусологи, микробиологи, специалисты в области молекулярной и клеточной биологии, фармакологи, представители экспертных и регуляторных учреждений, специалисты в области биофармацевтической индустрии, а также соискатели на звание научной степени. Тематика: Биологические лекарственные препараты Биотехнология Иммунология Вирусология Микробиология Вакцины Молекулярная биология Молекулярная терапия Генная терапия Клеточная терапия Инфекционные болезни Лабораторная диагностика Стандартизация препаратов
From the journal's Aims & Scope
Research area (LetPub): Medicine-General Medicine
Main research topics OpenAlex counts of recent articles; shares are approximate
- Biosimilars and Bioanalytical MethodsImmunology and Microbiology11.1%
- Analytical Methods in PharmaceuticalsChemistry10.2%
- Bacterial Infections and VaccinesImmunology and Microbiology6.2%
- Monoclonal and Polyclonal Antibodies ResearchMedicine6.2%
- Protein purification and stabilityBiochemistry, Genetics and Molecular Biology5.1%
- SARS-CoV-2 and COVID-19 ResearchMedicine4.2%
- Medical and Pharmaceutic StudiesPharmacology, Toxicology and Pharmaceutics4.2%
- History of Science and MedicineArts and Humanities4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| General Medicine | Q3 | 438/669 | 34th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
RSCI, ВАК, Белый списокPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 0.7LetPub ·
- SJR 2026-06
- 0.13LetPub ·
- SNIP 2026-06
- 0.32LetPub ·
- h-index
- 9OpenAlex ·
- i10-index
- 9OpenAlex ·
- 2-year mean citedness
- 0.69OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 552 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 35 | 35 | 104 |
| 2025 | 41 | 41 | 116 |
| 2024 | 37 | 37 | 126 |
| 2023 | 44 | 44 | 87 |
| 2022 | 32 | 32 | 55 |
| 2021 | 30 | 30 | 65 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 8 weeksLetPub ·
- Acceptance rate (publisher)
- 74%Publisher website ·
- Submission to first decision
- 8 daysPublisher website ·
- Submission to publication
- 177 daysPublisher website ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY | |
| LetPub | No APC | No | — |
Other charges and waivers (author guidelines)
- Other fees
- No other fees
- Page charges
- No page charges
- Submission fee
- No submission fee
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access
После успешного прохождения процесса рецензирования и одобрения редколлегией (см. схема редакционно-издательского процесса) рукописи публикуются бесплатно. Model summary
После успешного прохождения процесса рецензирования и одобрения редколлегией (см. схема редакционно-издательского процесса) рукописи публикуются бесплатно.
Source ↗Publisher website ·- Peer review
Двойное слепое рецензирование, минимум 2 рецензента на рукопись Model summary
Рецензирование: Двойное слепое Минимум 2 рецензента на рукопись
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
- Country or region
- Russian Federation
- Language
- Russian
- ISSN
- 2221-996X
- Electronic ISSN
- 2619-1156
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Biopreparaty Profilaktika diagnostika lechenie
How long does peer review take at Biopreparaty Profilaktika diagnostika lechenie?
Authors report an average review time of about 8 weeks; the journal's website gives an acceptance rate of 74%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Biopreparaty Profilaktika diagnostika lechenie?
According to LetPub and DOAJ records, Biopreparaty Profilaktika diagnostika lechenie is indexed in Scopus and DOAJ.
Is Biopreparaty Profilaktika diagnostika lechenie open access, and what is the APC?
Biopreparaty Profilaktika diagnostika lechenie is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .